Over the last years, the therapeutic potential of pharmaceuticals targeted at chromatin modifying enzymes, such as histone deacetylase (HDAC) inhibitors, in treatment of cognitive and behavioral impairments as well as psychiatric disorders such as anxiety, depression, fear, and schizophrenia has been repeatedly demonstrated [144–146]. This evidence concerns the gene HDAC9 and schizophrenia.